


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently amended) A compound of formula I



wherein

X is =CR⁰- or =N-;

each of R⁰, R¹, R², R³ and R⁴ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl;

C₃-C₈cycloalkyl; C₃-C₈cycloalkyl-C₁-C₈alkyl; hydroxyC₁-C₈alkyl; C₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkoxyC₁-C₈alkyl; arylC₁-C₈alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₈alkoxy, carboxy or C₁-C₈alkoxycarbonyl;

or R³ and R⁴ form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and having 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R¹, R² and R³, independently, is halogen; halo-C₁-C₈alkyl; C₁-C₈alkoxy; halo-C₁-C₈alkoxy; hydroxyC₁-C₈alkoxy; C₁-C₈alkoxyC₁-C₈alkoxy; aryl; arylC₁-C₈alkoxy; heteroaryl; heteroaryl-C₁-C₄alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy;

C₂-C₈alkoxycarbonyl; C₂-C₈alkylcarbonyl; -N(C₁-C₈alkyl)C(O) C₁-C₈alkyl; -N(R¹⁰)R¹¹; -CON(R¹⁰)R¹¹; -SO₂N(R¹⁰)R¹¹; or -C₁-C₄-alkylene-SO₂N(R¹⁰)R¹¹; wherein each of R¹⁰ and R¹¹ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkyl-C₁-C₈alkyl; C₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkoxyC₁-C₈alkyl; hydroxyC₁-C₈alkyl; (C₁-C₈alkyl)-carbonyl; arylC₁-C₈alkyl which optionally may be substituted on the ring by hydroxy, C₁-C₈alkoxy, carboxy or C₂-C₈alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R¹ and R² form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl group having one or two heteroatoms selected from N, O and S; or

R⁵ independently is hydrogen; halogen; cyano; C₁-C₈alkyl; halo-C₁-C₈alkyl; C₂-C₈alkenyl; C₂-C₈alkynyl; C₃-C₈cycloalkyl; C₃-C₈cycloalkylC₁-C₈alkyl; C₅-C₁₀arylc₁-C₈alkyl;

R^8 is hydrogen;

each of R^7 , R^8 and R^9 is independently hydrogen; hydroxy; C_1 - C_8 alkyl; C_2 - C_8 alkenyl; halo- C_1 - C_8 alkyl; C_1 - C_8 alkoxy; C_3 - C_8 cycloalkyl; C_3 - C_8 cycloalkyl C_1 - C_8 alkyl; aryl C_1 - C_8 alkyl; -Y-R¹² wherein Y is a direct bond or O and R¹² is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring having 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C_1 - C_8 alkoxy)-carbonyl; -N(C_1 - C_8 alkyl)-CO-NR¹⁰R¹¹; -CONR¹⁰R¹¹; -N(R¹⁰)(R¹¹); or R⁷ and R⁸ or R⁸ and R⁹, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring;

provided that one of R¹, R² or R³ is -CON(R¹⁰)R¹¹ or -SO₂N(R¹⁰)R¹¹;

in free form or salt form;


wherein

aryl represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl,

heteroaryl is a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring, and

wherein a heterocyclic ring is a 5 or 6 membered heterocyclic ring being saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II



wherein R¹, R², R³, R⁴, R⁵, R⁶ and X are as defined in claim 1, and Y is a leaving group;

with a compound of formula III



wherein R⁷, R⁸ and R⁹ are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

3. (Canceled)

4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.

5-7 (Canceled)

8. (Previously Presented) A method for treating breast cancer, comprising: administering to a subject in need thereof, a therapeutically effective amount of the compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

9. (Cancelled)